Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that revenue once again grew at double-digit rates thanks to increased demand for Vivitrol and Aristada. In addition, the company continues to make steady progress at moving its late-stage product candidates one step closer to the finish line.
Image source: Getty images.
Data source: Alkermes. GAAP = generally accepted accounting principles. EPS = earnings per share. NM = not meaningful due to negative figures.
Source: Fool.com
Alkermes plc Aktie
?
-0,44 %
Die Aktie ist durchaus ein Favorit unsere Community mit 23 Buy-Einschätzungen und 1 Sell-Einschätzungen.
Ein leicht positives Potenzial wird für Alkermes plc mit einem Kursziel von 46 € im Vergleich zu 42.76 € gesehen.
